News
-
-
-
PRESS RELEASE
Heidelberg Pharma’s Lead ADC Candidate HDP-101 Granted Fast Track Designation by US FDA for the Treatment of Multiple Myeloma
Heidelberg Pharma's lead ADC candidate HDP-101 granted Fast Track Designation by US FDA for the treatment of multiple myeloma. Accelerated review for innovative cancer therapy -
-
-
-
-
-
-